Looking for a reliable and efficient way to identify patients predisposed to developing cardiovascular diseases or intolerance to methotrexate therapy? Look no further than the Viennalab MTHFR RealFast™ Assays! Our assays accurately detect mutations in the methylenetetrahydrofolate reductase (MTHFR) gene, providing a crucial tool for optimizing treatment decisions.

Methotrexate therapy is commonly used for the treatment of various diseases, including cancer and rheumatoid arthritis. However, mutations in the MTHFR gene can lead to decreased enzyme activity, causing hyperhomocysteinemia and toxic side effects of methotrexate therapy. Elevated levels of homocysteine, an intermediary product of the methionine metabolism, are an established risk factor for atherosclerosis and arterial thrombosis.

Two common variants in the MTHFR gene, 677C>T and 1298A>C, contribute to reduced enzyme activity and hyperhomocysteinemia, which may affect methotrexate sensitivity and contribute to toxicity. Homozygosity for 677C>T or compound heterozygosity for 677C>T / 1298A>C conveys a significantly higher risk for negative side effects of methotrexate medication.

Identification of these genetic variants in the MTHFR gene is crucial for an adequate and safe methotrexate therapy. Trust in the Viennalab MTHFR RealFast™ Assays to provide you with accurate and reliable results, enabling you to make informed treatment decisions for your patients. Order now and experience the convenience and efficiency of RealFast™ technology!